Ascendis Pharma A/S announced new data from Week 214 of its Phase 2 PaTH Forward Trial, demonstrating that long-term treatment with TransCon PTH (palopegteriparatide) continued to provide a durable response in adults with hypoparathyroidism. The results were presented at the ESPE & ESE 2025 joint congress.
At Week 214, nearly all patients, 98%, continued to maintain normal albumin-adjusted serum calcium levels, and 93% remained independent from conventional therapy, defined as taking less than 600mg/day of calcium and no active vitamin D. The trial also showed sustained improvements in skeletal dynamics, with bone mineral density remaining within age- and sex-matched norms.
Furthermore, a clinically meaningful increase in estimated glomerular filtration rate (eGFR) from baseline was observed in 67.8% of participants, with changes evident as early as Week 4. TransCon PTH treatment was generally well-tolerated, with no new safety signals identified and most treatment-emergent adverse events being mild or moderate.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.